InvestorsHub Logo

Brando1975

10/23/17 7:39 PM

#3680 RE: lamboo39 #3679

Great article and I certainly think we deserve to be at a much higher market cap than 16 million. It will all come together with time!!

gew59

10/23/17 8:23 PM

#3681 RE: lamboo39 #3679

Great Find!!!!

I like these 2 paragraphs:

At some point, soon I see PKTX as a prime takeover candidate. Likely won’t happen until trial results begin to come out, which I would expect to see sometime in early in 2018. Novo Nordisk, (NYSE:NVO) and Eli Lilly, (NYSE:LLY) are both active in the Type 1 diabetes space and would be on the list of companies interested in acquiring them.

And:

It should also be noted that the CEO has funded a significant amount of the development himself, and owns 24% of the Company, and is only paying himself a salary of $1. That is unheard of among small-cap biotechs. Most of often a management team owns very little stock and pays themselves exorbitant salaries. It’s nice to see a management team be “all-in” like the folks at PKTX. With no debt and an extremely small burn, there is very little downside to the stock at this point. At these levels, it is a great place to accumulate and hold until we begin to see the data from the trials.